463 patents
Page 18 of 24
Utility
Anti-cancer Rna Aptamers
11 Nov 20
Provided herein, inter alia, are compounds capable of binding HSP70 (e.g. mHSP70) on a cell and internalizing into said cell.
John J. Rossi, Sorah Yoon, Nagy Habib
Filed: 17 Dec 19
Utility
Cars and Bispecific Antibodies for Treatment of Mantle Cell Lymphoma
11 Nov 20
Provided herein are, inter alia, compositions and methods for the treatment of cancer.
Hong Qin, Larry Kwak, Guowei Wei
Filed: 3 May 18
Utility
Chimeric Immunoreceptor Useful in Treating Human Cancers
11 Nov 20
The present invention relates to chimeric transmembrane immunoreceptors, named “zetakines,” comprised of an extracellular domain comprising a soluble receptor ligand linked to a support region capable of tethering the extracellular domain to a cell surface, a transmembrane region and an intracellular signalling domain.
Michael C. Jensen
Filed: 19 Dec 19
Utility
Artificial urinary sphincter device
9 Nov 20
An artificial urinary sphincter device is configured to be implanted in a relationship with a patient's urethra for the treatment of urinary incontinence.
Cassandra Rose Joung Meyer, Sophia Rose Williams, Jonathan Robert Wong, Meijing Maggie Liu, Risa Tom Egerter, Kevin Chan, Lori C. Bassman
Filed: 11 Oct 18
Utility
STAT3 inhibitors and uses thereof
9 Nov 20
Described herein, inter alia, are STAT-binding nucleic acids-including compositions and methods of using the same.
Marcin Tomasz Kortylewski, Piotr Marek Swiderski
Filed: 17 May 18
Utility
Treatment of CNS Lymphoma and Systemic Lymphoma with Intracerebroventricularly Administered CD19 Car
4 Nov 20
An improved method of treating cancers CD19 CAR T cells by administering the CD19 CAR T cells to the central nervous system, e.g., by intracerebroventricular administration, is described.
Xiuli Wang, Stephen J. Forman
Filed: 6 Nov 18
Utility
Thioindirubins
4 Nov 20
Disclosed herein inter alia are compositions and methods for treating cancer using thioindirubin derivatives.
Sangkil Nam, David Horne, Ravi Salgia, Alexios Leandros Skaltsounis, Nicolas Gaboriaud-Kolar, Panagiotis Gerolymatos, Nikolaos Lougiakis
Filed: 29 Aug 18
Utility
CS1 targeted chimeric antigen receptor-modified T cells
2 Nov 20
Chimeric antigen receptors for use in treating malignant melanoma and other cancers expressing CS1 are described.
Xiuli Wang, Stephen J. Forman
Filed: 6 Dec 15
Utility
Dithio ETP derivatives
2 Nov 20
Disclosed herein, inter alia, are compositions and methods of using the same for the treatment of cancer.
Sangkil Nam, David Horne, Larry Eugene Overman, Brad Loertscher
Filed: 14 Sep 17
Utility
Multivalent Oligonucleotide Assemblies
28 Oct 20
Provided herein, inter alia, are double stranded oligonucleotide molecules and methods of making the molecules.
Piotr Swiderski
Filed: 2 Dec 19
Utility
Short hairpin RNA compositions, methods of making and applications thereof
19 Oct 20
Provided herein are novel synthetic short hairpin RNA (shRNA) molecules and compositions and kits comprising such molecules, as well as methods of making and using these molecules, compositions, and kits.
Guihua Sun
Filed: 21 Oct 18
Utility
Tumor-selective CTLA-4 Antagonists
14 Oct 20
Provided herein are recombinant masking proteins and recombinant ligand proteins useful in treating cancer, neuro-degenerative disease, and cardiovascular disease.
John C. WILLIAMS, Ulrich RODECK, Kurt JENKINS
Filed: 2 Sep 19
Utility
Compounds and compositions including phosphorothioated oligodeoxynucleotide, and methods of use thereof
12 Oct 20
The present disclosure relates to a compound including a nucleic acid sequence conjugated to an anti-microRNA or a microRNA-mimic or a compound including a modified anti-microRNA sequence, compositions of such a compound, and method of treatment of a disease, and method of suppressing microRNA activity by the disclosed compound or composition.
Marcin Tomasz Kortylewski, Piotr Marek Swiderski, Guido Marcucci, Bin Zhang, Ya-Huei Kuo
Filed: 13 Oct 16
Utility
Stable Dithizone Solutions and Formulations and Methods for Their Use
7 Oct 20
An optimized Dipheylthiocarbazone or Dithizone (DTZ) solution was developed with preferred physical and chemical properties to characterize human islets and insulin producing cells differentiated from embryonic stem cells.
Ismail H. AL-ABDULLAH, Meirigeng QI, Bashar KHIATAH, Luis VALIENTE
Filed: 10 Mar 20
Utility
Genetically Stable Recombinant Modified Vaccinia Ankara (Rmva) Vaccines and Methods of Preparation Thereof
7 Oct 20
A vaccine comprising an immunologically effective amount of recombinant modified vaccinia Ankara (rMVA) virus which is genetically stable after serial passage and produced by a) constructing a transfer plasmid vector comprising a modified H5 (mH5) promoter operably linked to a DNA sequence encoding a heterologous foreign protein antigen, wherein the expression of said DNA sequence is under the control of the mH5 promoter; b) generating rMVA virus by transfecting one or more plasmid vectors obtained from step a) into wild type MVA virus; c) identifying rMVA virus expressing one or more heterologous foreign protein antigens using one or more selection methods for serial passage; d) conducting serial passage; e) expanding an rMVA virus strain identified by step d); and f) purifying the rMVA viruses from step e) to form the vaccine.
Don DIAMOND, Zhongde WANG
Filed: 29 Mar 20
Utility
Coaptive Surgical Sealing Tool
7 Oct 20
A coaptive surgical sealing tool may be similar to an ordinary hemostat with long (50, 60, 70 or 80 mm) thin jaws for sliding into the liver parenchyma, without tearing the larger blood vessels.
Gagandeep Singh
Filed: 20 Apr 20
Utility
Silica Nanoparticle with an Insoluble Drug
7 Oct 20
Disclosed herein, inter alia, are nanoparticle compositions (e.g., silica nanoparticles) including insoluble drug nanocrystals and methods of using the same for treating cancer.
Pamela TIET, Jacob BERLIN
Filed: 1 Feb 18
Utility
COSTIMULATORY CHIMERIC ANTIGEN RECEPTOR T CELLS TARGETING IL13R-alpha-2
7 Oct 20
Chimeric transmembrane immunoreceptors (CAR) which include an extracellular domain that includes IL-13 or a variant thereof that binds interleukin-13Rα2 (IL13Rα2), a transmembrane region, a costimulatory domain and an intracellular signaling domain are described.
Christine E. Brown, Stephen J. Forman
Filed: 5 May 20
Utility
Methods and compositions for treatment of breast cancer
5 Oct 20
Provided are methods of treating breast cancer in a subject in need thereof comprising administering to the subject an effective amount of an inhibitor of miR-105 or an inhibitor of miR-122 are provided.
Shizhen Emily Wang, Xiwei Wu
Filed: 9 Mar 14
Utility
Chimeric Antigen Receptors Targeted to Psca
30 Sep 20
Chimeric transmembrane immunoreceptors (CAR) targeted to PSCA are described.
Saul J. Priceman, Christine E. Brown, Stephen J. Forman
Filed: 5 Oct 16